Incyte Corp - Company Profile
Powered by
All the data and insights you need on Incyte Corp in one report.
- Save hours of research time and resources with
our up-to-date Incyte Corp Strategy Report
- Understand Incyte Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Incyte Corp (Incyte) is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
Incyte Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Ruxolitinib | Jakavi |
Ponatinib | Jakafi |
Capmatinib | Iclusig |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In April, the company entered into a partnership with CMS Skinhealth for the advancement and commercialization of povorcitinib. |
2024 | Others | In February, the company introduced The Unseen Journey. |
2024 | Contracts/Agreements | In February, the company signed an agreement with MorphoSys AG for global rights for tafasitamab. |
Competitor Comparison
Key Parameters | Incyte Corp | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Amgen Inc | Gilead Sciences Inc |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
City | Wilmington | Basel | Kenilworth | Thousand Oaks | Foster City |
State/Province | Delaware | - | New Jersey | California | California |
No. of Employees | 2,524 | 103,605 | 72,000 | 26,700 | 18,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Herve Hoppenot | Chief Executive Officer; President; Chairman | Executive Board | 2014 | 63 |
Christiana Stamoulis | Executive Vice President; Chief Financial Officer | Senior Management | 2019 | 52 |
Steven H. Stein, M.D. | Executive Vice President; Chief Medical Officer | Senior Management | 2015 | 56 |
Dashyant Dhanak, Ph.D. | Executive Vice President; Chief Scientific Officer | Senior Management | 2018 | 62 |
Pablo J. Cagnoni, M.D | Head - Research and Development; President | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward